Dr Reddy’s Is Latest Player To Pivot To Trade Generics In India

Cipla, Torrent Among Firms Pushing Unbranded Generics In India Amid Headwinds

Dr Reddy’s Laboratories says it will work closely with its channel partners to ensure availability of its products, after entering into the unbranded, trade generics business in India with the launch of a new dedicated division, ‘RGenX’.

Indian flag
• Source: Shutterstock

Dr. Reddy's Laboratories is looking to further the company’s goal of reaching over 1.5 billion patients by 2030 after entering into the trade generics business in India with the launch of a new dedicated division, ‘RGenX’.

Moving forward, the Indian firm's branded medicines will be sold through the trade generics route, including a product brand name...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

Latest EMA Biosimilar Nods Come For Henlius, Alteogen And Biocon

 
• By 

Denosumab, aflibercept and ustekinumab biosimilars received positive opinions from the EMA’s CHMP at its meeting in July, along with an Opsumit generic from Accord.

The Generics Bulletin Top 50, Part Two: Leading Players Leapfrog The Competition

 
• By 

In the second instalment of Generics Bulletin’s Top 50 ranking for 2025, we see plenty of movement among our mid-table collection of companies.

Gateway To Africa: Natco Bids For 35.75% Of Adcock Ingram

 

Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.

The Generics Bulletin Top 50, Part One: German Giants Rise Up The Ranks

 
• By 

Two leading German generics and biosimilars giants were the big movers in our top ten ranking of off-patent industry leaders for 2025. We reveal the latest developments among the top players in the first instalment of this year’s Generics Bulletin Top 50.

More from Products

Sun Strikes Further US Price-Fixing Settlement For $200m

 
• By 

The latest development in the long-running US generic price-fixing saga has seen Sun Pharma agree a $200m settlement in connection with an end purchaser action in Pennsylvania.

Just One Week To Go! Entry Deadline Looms For GGB Awards 2025

 
• By 

There is now just one week left to submit entries to the Global Generics & Biosimilars Awards 2025, with the entry deadline set for August 1.

UK Xtandi Patent Stands Strong As Accord, Sandoz, Teva Lose Appeal

 
• By 

The Court of Appeal in London has upheld a key UK patent shielding Astellas’ Xtandi, rejecting claims by a trio of generic drugmakers that it was obvious after finding that the generics firms’ expert analysis was tainted by hindsight.